Loading...
•
Jun 30, 2024
Tyra Biosciences Q2 2024 Earnings Report
Tyra Biosciences reported financial results for Q2 2024 and highlighted corporate progress.
Key Takeaways
Tyra Biosciences reported a net loss of $18.7 million for the second quarter of 2024. The company's cash, cash equivalents, and marketable securities were $373.8 million as of June 30, 2024.
SURF301 Phase 1 initial results and ACH IND submission expected in 2H24.
Reported preclinical proof-of-concept with TYRA-300 in HCH, demonstrating increases in long bone length and binding against the HCH altered protein.
IND cleared for TYRA-430, an FGFR4/3 biased inhibitor for HCC.
Announced Chief Medical Officer transition plan; search for an external candidate underway.
Tyra Biosciences
Tyra Biosciences
Forward Guidance
TYRA's current cash, cash equivalents and marketable securities are expected to allow TYRA to execute on its plans through at least 2026.